Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia

Completed · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.

Key facts

Study ID

NCT00580125

Run by

Pfizer

People needed

164

Starts

2007-11-01

Expected to finish

2008-09-01

Last updated by the study team

2012-04-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Key inclusion criteria include:
• Have a current diagnosis of schizophrenia.
• Increase in symptoms over the past 2-4 weeks.
• Willing to remain inpatients for the duration of the trial.

You may not qualify if…

• Subjects with a current DSM-IV axis I diagnosis other than schizophrenia
• Subjects who meet the DSM-IV criteria for psychoactive substance abuse and dependence
• Subjects with a history of treatment resistant schizophrenia
• Females of childbearing potential

Where it is running

• Pfizer Investigational Site — Garden Grove, California, United States
• Pfizer Investigational Site — Torrance, California, United States
• Pfizer Investigational Site — Washington D.C., District of Columbia, United States
• Pfizer Investigational Site — Detroit, Michigan, United States
• Pfizer Investigational Site — Bridgeton, Missouri, United States
• Pfizer Investigational Site — Florissant, Missouri, United States
• Pfizer Investigational Site — Saint Charles, Missouri, United States
• Pfizer Investigational Site — Brooklyn, New York, United States
• Pfizer Investigational Site — Bangalore, Karnataka, India
• Pfizer Investigational Site — Mangalore, Karnataka, India
• Pfizer Investigational Site — Udupi, Karnataka, India
• Pfizer Investigational Site — Pune, Maharashtra, India
• Pfizer Investigational Site — Pune, India
• Pfizer Investigational Site — Gatchina District, Leningradskaya Oblast', Russia
• Pfizer Investigational Site — Khot'kovo, Russia
• Pfizer Investigational Site — Moscow, Russia
• Pfizer Investigational Site — Saint Petersburg, Russia
• Pfizer Investigational Site — Saint Petersburg, Russia
• Pfizer Investigational Site — Simferopol, Autonomous Republic of Crimea, Ukraine
• Pfizer Investigational Site — Kiev, Ukraine, Ukraine
• Pfizer Investigational Site — Dnipropetrovsk, Ukraine
• Pfizer Investigational Site — Donetsk, Ukraine
• Pfizer Investigational Site — Kharkiv, Ukraine
• Pfizer Investigational Site — Kharkiv, Ukraine
• Pfizer Investigational Site — Kyiv, Ukraine

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.